CARDIFF ONCOLOGY, INC. (CRDF) Quick Ratio
- Quick ratio · latest quarter: Value 2.37×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.37× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $25.57M ÷ $10.80M ≈ 2.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 25.57M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 10.80M USD | Liabilities, Current |
| Cash and equivalents | 9.20M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 16.18M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 189.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.57M | $10.80M | $9.20M | $16.18M | $189.00K | (m) | 2.37× |
| 2026-03-31 | $32.63M | $14.46M | $8.54M | $23.90M | $191.00K | (m) | 2.26× |
| 2025-12-31 | $49.60M | $16.39M | $17.47M | $31.95M | $182.00K | (m) | 3.03× |
| 2025-09-30 | $52.10M | $14.71M | $10.13M | $41.71M | $254.00K | (m) | 3.54× |
| 2025-06-30 | $61.69M | $16.67M | $10.78M | $50.38M | $526.00K | (m) | 3.70× |
| 2025-03-31 | $67.58M | $13.29M | $24.09M | $43.08M | $405.00K | (m) | 5.08× |
| 2024-12-31 | $86.25M | $13.43M | $51.47M | $34.01M | $773.00K | (m) | 6.42× |
| 2024-09-30 | $49.44M | $12.53M | $13.04M | $35.78M | $618.00K | (m) | 3.95× |
| 2024-06-30 | $59.08M | $12.52M | $25.50M | $33.12M | $451.00K | (m) | 4.72× |
| 2024-03-31 | $61.75M | $11.84M | $18.66M | $42.70M | $393.00K | (m) | 5.21× |
| 2023-12-31 | $48.25M | $10.44M | $21.66M | $26.31M | $288.00K | (m) | 4.62× |
| 2023-09-30 | $53.14M | $9.02M | $15.23M | $37.71M | $198.00K | (m) | 5.89× |
| 2023-06-30 | $60.83M | $9.12M | $19.37M | $41.30M | $161.00K | (m) | 6.67× |
| 2023-03-31 | $66.21M | $8.15M | $15.02M | $50.52M | $676.00K | (m) | 8.13× |
| 2022-12-31 | $101.04M | $7.81M | $16.35M | $83.92M | $771.00K | (m) | 12.94× |
| 2022-09-30 | $107.87M | $8.24M | $18.72M | $88.50M | $650.00K | (m) | 13.08× |
| 2022-06-30 | $116.24M | $8.48M | $20.96M | $94.72M | $551.00K | (m) | 13.71× |
| 2022-03-31 | $114.91M | $6.66M | $20.05M | $94.41M | $447.00K | (m) | 17.24× |
| 2021-12-31 | $108.06M | $6.56M | $11.94M | $95.58M | $535.00K | (m) | 16.48× |
| 2021-09-30 | (m) | $5.04M | $13.16M | (m) | $395.00K | (m) | (m) |
| 2021-06-30 | (m) | $4.58M | $10.58M | (m) | $308.00K | (m) | (m) |
| 2021-03-31 | (m) | $4.48M | $14.66M | (m) | $242.00K | (m) | (m) |
| 2020-12-31 | (m) | $6.12M | $130.98M | (m) | $320.46K | (m) | (m) |
| 2020-09-30 | (m) | $5.44M | $36.41M | (m) | $204.37K | (m) | (m) |
| 2020-06-30 | (m) | $4.96M | $27.75M | (m) | $109.33K | (m) | (m) |
| 2020-03-31 | (m) | $4.88M | $9.28M | (m) | $106.43K | (m) | (m) |
| 2019-12-31 | (m) | $4.78M | $10.20M | (m) | $203.48K | (m) | (m) |
| 2019-09-30 | (m) | $4.17M | $9.03M | (m) | $152.04K | (m) | (m) |
| 2019-06-30 | (m) | $3.69M | $10.79M | (m) | $122.28K | (m) | (m) |
| 2019-03-31 | (m) | $3.28M | $11.33M | (m) | $115.68K | (m) | (m) |
| 2018-12-31 | (m) | $2.97M | $11.45M | (m) | $167.75K | (m) | (m) |
| 2018-09-30 | (m) | $2.67M | $15.07M | (m) | $128.58K | (m) | (m) |
| 2018-06-30 | (m) | $3.22M | $18.49M | (m) | $124.08K | (m) | (m) |
| 2018-03-31 | (m) | $3.85M | $6.66M | (m) | $114.34K | (m) | (m) |
| 2017-12-31 | (m) | $3.95M | $8.23M | (m) | $77.09K | (m) | (m) |
| 2017-09-30 | (m) | $5.08M | $7.43M | (m) | $178.13K | (m) | (m) |
| 2017-06-30 | (m) | $7.46M | $7.78M | (m) | $157.44K | (m) | (m) |
| 2017-03-31 | (m) | $8.96M | $10.18M | (m) | $80.35K | (m) | (m) |
| 2016-12-31 | (m) | $7.80M | $13.92M | (m) | $100.46K | (m) | (m) |
| 2016-09-30 | (m) | $6.56M | $22.57M | (m) | $85.15K | (m) | (m) |
| 2016-06-30 | (m) | $10.89M | $22.58M | (m) | $158.54K | (m) | (m) |
| 2016-03-31 | (m) | $10.12M | $59.99M | (m) | $61.94K | (m) | (m) |
| 2015-12-31 | (m) | $8.20M | $67.49M | (m) | $98.74K | (m) | (m) |
| 2015-09-30 | (m) | $6.97M | $74.15M | (m) | $66.97K | (m) | (m) |
| 2015-06-30 | (m) | $4.95M | $41.29M | (m) | $99.72K | (m) | (m) |
| 2015-03-31 | (m) | $5.31M | $44.00M | (m) | $59.39K | (m) | (m) |
| 2014-12-31 | (m) | $4.49M | $27.29M | (m) | $56.69K | (m) | (m) |
| 2014-10-31 | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.12M | $31.16M | (m) | $62.37K | (m) | (m) |
| 2014-07-31 | (m) | (m) | $33.60M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.98M | $34.67M | (m) | $59.91K | (m) | (m) |
| 2014-04-30 | (m) | (m) | $21.90M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $2.03M | $22.87M | (m) | $129.30K | (m) | (m) |
| 2013-12-31 | (m) | $2.01M | $25.84M | (m) | $78.99K | (m) | (m) |
| 2013-09-30 | (m) | $1.36M | $27.80M | (m) | $69.57K | (m) | (m) |
| 2013-06-30 | (m) | $1.46M | $8.30M | (m) | $56.50K | (m) | (m) |
| 2013-03-31 | (m) | $1.18M | $9.16M | (m) | $58.06K | (m) | (m) |
| 2012-12-31 | (m) | $730.37K | $10.82M | (m) | $168.38K | (m) | (m) |
| 2012-09-30 | (m) | $757.54K | $7.82M | (m) | $128.19K | (m) | (m) |
| 2012-06-30 | (m) | $1.24M | $9.30M | (m) | $106.03K | (m) | (m) |
| 2012-03-31 | (m) | $1.53M | $586.78K | (m) | $76.53K | (m) | (m) |
| 2011-12-31 | (m) | $1.43M | $700.37K | (m) | $99.14K | (m) | (m) |
| 2011-09-30 | (m) | (m) | $157.47K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $15.28K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $88.52K | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $58.70K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |